Fluticasone Furoate/Umeclidinium/Vilanterol Initiation Following a COPD Exacerbation: Benefits of Prompt Initiation on COPD Outcomes.

Results for the overall observation period are shown in Supplementary Table S4 . Kaplan–Meier estimates show similar results up to 12 months post-index, with a 1-day delay in FF/UMEC/VI initiation associated with a 0.32%, 0.32%, and 0.33% increase in the risk of experiencing an overall, moderate, and severe exacerbation, respectively (Table 3 ). All-Cause and COPD-Related Medical Costs Over a mean of 10.8 months post-index (up to 12 months’ follow-up analysis), total all-cause healthcare costs PPPY were trending lower but the difference did not reach statistical significance for patients in the prompt versus delayed weighted cohort ($34,666 vs. $37,233; cost difference $2567; P = 0.160) (Table 4 ).

also in 111,027 other papers